✨ Free AI Report
Imunon, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Imunon, Inc.
Company Research

Imunon, Inc.: Business Overview, Financials & Competitive Analysis

Imunon, Inc. scores 4/10 on the AskCyborg Cyborg Score (Weak). Early-stage immunotherapy play with promising ovarian cancer data but severe liquidity constraints and execution risk overshadow potential upside. Despite promising clinical data showing OS benefit in Phase 2, Imunon faces significant near-term headwinds: minimal market capitalization (~$15M), critical cash runway through Q1 2026, severe equity dilution, and thin operating margins.

What is Imunon, Inc.'s industry? Imunon, Inc. (imunon.com) operates in Biotechnology / Immuno-Oncology. AskCyborg classifies Imunon, Inc. under Biotechnology / Immuno-Oncology in its company registry.

Imunon is a clinical-stage biotechnology company developing DNA-mediated immunotherapies with a focus on immuno-oncology and vaccine candidates. The company's lead program, IMNN-001, is a DNA-based interleukin-12 (IL-...

4/ 10Weak

Cyborg Score thesis

Early-stage immunotherapy play with promising ovarian cancer data but severe liquidity constraints and execution risk overshadow...

Read the full analyst-debate transcript →
Industry Biotechnology / Immuno-Oncology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Imunon, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Imunon, Inc.

AskCyborg analysts argue the bull and bear cases for Imunon, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Imunon, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Imunon, Inc. Overview

Pro stress-test →

Imunon is a clinical-stage biotechnology company developing DNA-mediated immunotherapies with a focus on immuno-oncology and vaccine candidates. The company's lead program, IMNN-001, is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 3 development (OVATION 3 trial) for advanced ovarian cancer, showing preliminary data demonstrating a median 13-month overall survival benefit.

Strategic Profile

Pro stress-test →

Imunon leverages proprietary plasmid DNA technology platforms (TheraPlas and PlaCCine) to deliver cytokines and therapeutic proteins for cancer and infectious disease applications. The company is strategically positioned to address unmet needs in ovarian cancer treatment and next-generation vaccines, though it faces typical clinical-stage biotech risks including funding, trial execution, and regulatory approval hurdles.

Competitive Landscape

Pro stress-test →

Imunon competes in the ovarian cancer immunotherapy space against established players and clinical-stage biotech firms developing checkpoint inhibitors and combination therapies. Key competitors include Roche/Genentech, Merck, AstraZeneca, and emerging players with similar DNA/gene therapy approaches. Imunon's differentiation lies in its DNA-mediated delivery platform, though clinical efficacy versus standard checkpoint combinations remains unproven in Phase 3.

Industry Context

Imunon, Inc. operates in Biotechnology / Immuno-Oncology.

Key facts

Founded: 1999 · Headquarters: Lawrenceville, New Jersey, US · Market cap: $15.21M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Imunon, Inc..

  • Lead candidate IMNN-001 demonstrated 13-month median overall survival benefit in Phase 2 OVATION 2 trial, supporting pivotal Phase 3 OVATION 3 enrollment
  • Severe liquidity crisis: Q3 2025 cash of $5.3M funds operations only through Q1 2026; company actively pursuing selective financing
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Nov 2025Presented positive translational and clinical data at R&D Day; Phase 3 OVATION 3 enrollment expansion underway
  • Sept 2025Q3 results showed net loss of $3.4M with 30% reduction in operating expenses; cash position $5.3M
  • +2 moreTrack every material event for Imunon, Inc. as it happens. Explore monitoring →
Get alerted when Imunon, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Bevacizumab (Avastin)Anti-VEGF monoclonal antibody for ovarian cancer; standard-of-care combination partner→Keytruda (Pembrolizumab)Checkpoint inhibitor; established in ovarian cancer frontline and maintenance therapy→Imjudo (Tremelimumab) + Imfinzi (Durvalumab)CTLA-4/PD-L1 combination; recent approval in advanced ovarian cancer→

Compare Imunon, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Imunon, Inc. operates in Biotechnology / Immuno-Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology / Immuno-Oncology research →
NEW · MCP server

Ask your AI assistant about Imunon, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Imunon, Inc. and its top competitor on Cyborg Score”
“What did Imunon, Inc. do this quarter?”
“Is Imunon, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Imunon, Inc. do?+
Imunon is a clinical-stage biotechnology company developing DNA-mediated immunotherapies with a focus on immuno-oncology and vaccine candidates. The company's lead program, IMNN-001, is a DNA-based interleukin-12 (IL-...
What is Imunon, Inc.'s Cyborg Score?+
Imunon, Inc. has a Cyborg Score of 4/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Imunon, Inc.'s main competitors?+
Named competitors include Bevacizumab (Avastin), Keytruda (Pembrolizumab), Imjudo (Tremelimumab) + Imfinzi (Durvalumab). The full competitive landscape is in the AskCyborg report.
How can I get the full Imunon, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Imunon, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Imunon, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score